CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [21] Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
    Goede, V.
    Fischer, K.
    Busch, R.
    Jaeger, U.
    Dilhuydy, M-S
    Wickham, N.
    De Guibert, S.
    Ritgen, M.
    Langerak, A. W.
    Bieska, G.
    Engelke, A.
    Humphrey, K.
    Wenger, M.
    Hallek, M.
    LEUKEMIA, 2013, 27 (05) : 1172 - 1174
  • [22] Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
    V Goede
    K Fischer
    R Busch
    U Jaeger
    M-S Dilhuydy
    N Wickham
    S De Guibert
    M Ritgen
    A W Langerak
    G Bieska
    A Engelke
    K Humphrey
    M Wenger
    M Hallek
    Leukemia, 2013, 27 : 1172 - 1174
  • [23] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan A.
    Borthakur, Gautam
    Bose, Prithviraj
    Estrov, Zeev
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Garg, Naveen
    Wang, Xuemei
    Gandhi, Varsha
    Plunkett, William
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Lopez, Wanda
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2017, 130
  • [24] Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
    Flynn, Joseph M.
    Byrd, John C.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Tyson, Nicola
    Hirata, Jamie H.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
    Cramer, Paula
    von Tresckow, Julia
    Robrecht, Sandra
    Bahlo, Jasmin
    Furstenau, Moritz
    Langerbeins, Petra
    Pflug, Natali
    Al-Sawaf, Othman
    Heinz, Werner J.
    Vehling-Kaiser, Ursula
    Durig, Jan
    Tausch, Eugen
    Hensel, Manfred
    Sasse, Stephanie
    Fink, Anna-Maria
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    HAEMATOLOGICA, 2021, 106 (02) : 543 - 554
  • [26] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
    Jain, Nitin
    Thompson, Philip
    Burger, Jan
    Borthakur, Gautam
    Bose, Prithviraj
    Estrov, Zeev
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Garg, Naveen
    Wang, Xuemei
    Gandhi, Varsha
    Plunkett, William
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Lopez, Wanda
    Kantarjian, Hagop
    O'Brien, Susan
    Keating, Michael
    Wierda, William
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S13 - S14
  • [27] Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial.
    Goede, Valentin
    Fischer, Kirsten
    Raymonde, Busch
    Ulrich, Jaeger
    Dilhuydy, Marie-Sarah
    Wickham, Nicholas
    De Guibert, Sophie
    Fink, Anna Maria
    Hagist, Susanne
    Pflug, Natali
    Bahlo, Jasmin
    Kranz, Gabriele
    Bieska, Gabriel
    Humphrey, Kathryn
    Bishop, Helen
    Wenger, Michael
    Hallek, Michael
    BLOOD, 2010, 116 (21) : 597 - 597
  • [28] Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Bosch, Francesc
    Illmer, Thomas
    Turgut, Mehmet
    Cortelezzi, Agostino
    Lasserre, Susan F.
    Truppel-Hartmann, Anna
    Leblond, Veronique
    Foa, Robin
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [29] GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
    Jamie B. Oughton
    Laura Collett
    Dena R. Howard
    Anna Hockaday
    Talha Munir
    Kathryn McMahon
    Lucy McParland
    Claire Dimbleby
    David Phillips
    Andy C. Rawstron
    Peter Hillmen
    Trials, 18
  • [30] GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
    Oughton, Jamie B.
    Collett, Laura
    Howard, Dena R.
    Hockaday, Anna
    Munir, Talha
    McMahon, Kathryn
    McParland, Lucy
    Dimbleby, Claire
    Phillips, David
    Rawstron, Andy C.
    Hillmen, Peter
    TRIALS, 2017, 18
12345